Aachen, Germany \u2014 Protem\u00adbis GmbH (Protem\u00adbis), a cardio\u00advas\u00adcu\u00adlar medi\u00adcal device company, has raised EUR 30 million in a Series B finan\u00adcing round. The startup will use the funds to advance the initia\u00adtion of the PROTEMBO Inves\u00adti\u00adga\u00adtio\u00adnal Device Exemp\u00adtion (IDE) Pivo\u00adtal Trial (NCT05873816). The finan\u00adcing round was split into two sepa\u00adrate capi\u00adtal increa\u00adses, both of which have now been comple\u00adted. A Euro\u00adpean consor\u00adtium of VC inves\u00adtors led the invest\u00adment, inclu\u00adding Segu\u00adlah Medi\u00adcal Acce\u00adle\u00adra\u00adtion from Sweden, XGEN Venture from Italy and the Tech\u00adVi\u00adsion Fund from Germany. Other inves\u00adtors include Copa\u00adrion, seve\u00adral large family offices, angel inves\u00adtors and a multi\u00adna\u00adtio\u00adnal medi\u00adcal tech\u00adno\u00adlogy group.<\/p>\n
\u201cWe are plea\u00adsed to announce the closing of the finan\u00adcing round and thank our exis\u00adting and new inves\u00adtors for their trust,\u201d said Karl von Mangoldt <\/strong>and Conrad Rasmus, Co-CEOs of Protem\u00adbis<\/strong>. \u201cIt reflects the fact that the field of cere\u00adbral embo\u00adlic protec\u00adtion is thri\u00adving and that future growth will be driven by youn\u00adger and lower-risk pati\u00adents who do not accept the risk of brain injury when opting for trans\u00adca\u00adthe\u00adter aortic valve replacement.\u201d<\/p>\n In addi\u00adtion, Dr. Keith D. Dawkins<\/strong>, MD, was appoin\u00adted to the Protem\u00adbis Advi\u00adsory Board. Dawkins has more than 35 years of expe\u00adri\u00adence in the cardio\u00advas\u00adcu\u00adlar field. He was a prac\u00adti\u00adcing cardio\u00adlo\u00adgist in the UK for over 20 years, a Fulbright Scho\u00adlar at Stan\u00adford Univer\u00adsity, Presi\u00addent of the British Cardio\u00advas\u00adcu\u00adlar Inter\u00adven\u00adtion Society and author of more than 750 acade\u00admic publi\u00adca\u00adti\u00adons and presen\u00adta\u00adti\u00adons. Dawkins has been Chief Medi\u00adcal Offi\u00adcer (CMO) of Shock\u00adwave since 2019. Previously, he held a senior posi\u00adtion as Global CMO at Boston Scien\u00adti\u00adfic since 2008. He is also a member of the super\u00advi\u00adsory boards of Ventric Health LLC and Jena\u00adValve Tech\u00adno\u00adlogy Inc. and as Chair\u00adman of Innov\u00adHe\u00adart s.r.l. Dawkins will contri\u00adbute his exper\u00adtise to Protem\u00adbis\u2019 clini\u00adcal stra\u00adte\u00adgies and pre-commer\u00adcial programs once the IDE study is completed.<\/p>\n \u201cHaving such a visio\u00adnary leader as Dr. Dawkins on our advi\u00adsory board demons\u00adtra\u00adtes the possi\u00adbi\u00adli\u00adties that cere\u00adbral embo\u00adlic protec\u00adtion (CEP) holds for future trans\u00adca\u00adthe\u00adter thera\u00adpies. We look forward to working closely toge\u00adther as the field evol\u00adves and our supe\u00adrio\u00adrity trial gains momen\u00adtum,\u201d says Azin Parhiz\u00adgar, PhD and Advi\u00adsory Board Chair.<\/p>\n \u201cI have been empha\u00adsi\u00adzing the need to protect the brain from new lesi\u00adons during trans\u00adca\u00adthe\u00adter aortic valve repla\u00adce\u00adment (TAVR) for many years and am ther\u00ade\u00adfore deligh\u00adted to be joining Protem\u00adbis,\u201d says Dawkins. \u201cThe ProtEmbo system and clini\u00adcal trial design are inno\u00adva\u00adtive and I am confi\u00addent that they will greatly trans\u00adform the field of cere\u00adbral embo\u00adlic protec\u00adtion and elimi\u00adnate or miti\u00adgate many of the current issues of concern to the medi\u00adcal profession.\u201d<\/p>\n About Protem\u00adbis!<\/strong><\/p>\n The start-up Protem\u00adbis, foun\u00added by Karl von Mangoldt and Conrad Rasmus, has set itself the goal of offe\u00adring a simple and relia\u00adble solu\u00adtion to protect pati\u00adents from brain inju\u00adries during left-sided heart surgery. To this end, the start-up is deve\u00adlo\u00adping the ProtEmbo\u00ae Cere\u00adbral Protec\u00adtion System, which is curr\u00adently under\u00adgo\u00ading clini\u00adcal trials. https:\/\/protembis.com<\/p>\n","protected":false},"excerpt":{"rendered":" Aachen, Germany \u2014 Protem\u00adbis GmbH (Protem\u00adbis), a cardio\u00advas\u00adcu\u00adlar medi\u00adcal device company, has raised EUR 30 million in a Series B finan\u00adcing round. The startup will use the funds to advance the initia\u00adtion of the PROTEMBO Inves\u00adti\u00adga\u00adtio\u00adnal Device Exemp\u00adtion (IDE) Pivo\u00adtal Trial (NCT05873816). The finan\u00adcing round was split into two sepa\u00adrate capi\u00adtal increa\u00adses, both of which [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":51081,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1368,1369,1373],"tags":[],"class_list":["post-51083","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-consultants-auditors","category-investors","category-venture-capital-en"],"yoast_head":"\n